Coronavirus / COVID

Non-pharmaceutical interventions (NPIs) are not only effective against COVID-19, but also respiratory infections.

Phase 2 data hints the immune response-modulating therapy could play a role in burdened hospital settings.

Further evidence demonstrating the lack of efficacy of hydroxychloroquine as a treatment for coronavirus disease 2019 (COVID-19) was detailed in a new randomized, multicenter, blinded, placebo-controlled study published in JAMA.

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.

Findings from Michigan show financial, mental health, and cardiopulmonary impacts are prevalent in patients 2 months after hospital care.

Blood pressure medication adherence should continue for patients with COVID-19, and atrial fibrillation and atrial flutter can worsen outcomes in hospitalized COVID-19 patients.

Large cohort study quantifies risk for hospital admission for COVID-19 among healthcare workers and members of their households.

The anti-inflammatory drug infliximab may have a role in treating COVID-19, according to a new study examining how a key enzyme influences viral entry and gut inflammation.

Patients with rheumatic diseases do not appear to face heightened risk from COVID-19, even if they are taking immunosuppressant medications, new data indicates.

The country halted the Sinovac investigational vaccine due to what was being reported as a serious adverse event.

Alzheimer’s disease, dementia, and genetic variations in areas key to viral infection are risk factors for severe COVID-19 a new study suggests.

Bamlanivimab should be administered as soon as possible after a positive test, and within 10 days of developing symptoms, Eli Lilly said.

The federal agency announced Novavax’s, NVX-CoV2373, was granted this designation.

The new research letter also highlights a concerning rate of infection among Latino patients.

The company is still awaiting its threshold for total COVID-19 infections in its 44,000-patient assessment. Nonetheless, they believe they have made history.

A new survey shows just 2% of children with rheumatic disease reported COVID-19 positive test results or symptoms through early May.

New findings show subsequent drops in incidence, hospitalizations, and mortalities once the state set stay-at-home orders, mask mandates, and contact tracing.

The final report of remdesivir trial supports its approved treatment for COVID-19 after preliminary findings enabled emergency use authorization.

A similar shutdown seems inevitable, but there may be an alternative.

The test simultaneously recognizes the S1 and S2 subunits of the virus' spike protein in one sample, providing better sensitivity.

Neurological symptoms of COVID-19 ranging from dizziness to microclots could be the result of destabilization of the blood-brain barrier caused by virus spike proteins circulating in the blood.

The country moves into a difficult phase of the pandemic as fall slides into winter with no national mandates and no vaccine.

In a survey, a panel of experts sees the American response as problematic and weighs in on universal masking.